Indivior PLC Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Net Revenue: $314 million, up 2% year-over-year.

SUBLOCADE Net Revenue: $219 million, a 15% increase from Q3 2024, driven by an 8% growth in dispense volume.

Adjusted EBITDA: $120 million, a 14% increase year-over-year.

Operating Expenses: Non-GAAP operating expenses were $145 million, down 3% from the previous year.

Cash Position: Gross cash and investments increased to $473 million, up from $347 million at year-end 2024.

2Strategic Updates and Business Highlights

Indivior is progressing with its Indivior Action Agenda, focusing on simplifying operations and enhancing commercial execution, particularly for SUBLOCADE.

The company has implemented cost-saving measures expected to reduce operating expenses by at least $150 million annually starting in 2026.

A new direct-to-consumer campaign, "Move Forward in Recovery," was launched to raise awareness of SUBLOCADE.

The organization has streamlined operations, including the cancellation of its London Stock Exchange listing and restructuring R&D and medical affairs.

3Forward Guidance and Outlook

Raised 2025 Financial Guidance: Total net revenue is now expected to be between $1.18 billion and $1.22 billion, with SUBLOCADE net revenue projected at $825 million to $845 million (10% growth at midpoint).

Adjusted EBITDA Guidance: Increased to $400 million to $420 million, reflecting a 15% growth versus 2024.

The company plans to provide full-year 2026 financial guidance in early January 2026, with expectations for increased profitability and cash generation.

4Bad News, Challenges, or Points of Concern

Pricing Pressure: While SUBOXONE Film pricing has stabilized, there are ongoing concerns regarding market dynamics and potential future price erosion.

Operational Complexity: The organization is undergoing significant restructuring, which could pose risks during the transition period.

Market Competition: Although SUBLOCADE holds a 75% market share in the LAI category, the overall market penetration remains low at 8%, indicating room for growth but also competitive pressures.

5Notable Q&A Insights

Cost Reduction Breakdown: The $150 million in operating expense cuts primarily stem from a 32% reduction in headcount, discontinuation of OPVEE marketing, and optimization of the Rest of World business.

Commercial Strategy: The focus is on improving commercial execution across both Medicaid and commercial channels, with an emphasis on increasing the number of prescribers and their patient loads.

R&D Spending: Future R&D expenditures will be streamlined, with preserved capabilities to advance Phase II assets into Phase III if warranted.

Market Growth: There is optimism regarding SUBLOCADE's growth trajectory, with indications that improved commercial execution and label updates are positively impacting prescribing patterns. Overall, Indivior's Q3 2025 results reflect a solid performance, driven by SUBLOCADE's growth, while the company prepares for a strategic transition into a new phase aimed at accelerating growth and profitability.